<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093704</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000389476</org_study_id>
    <secondary_id>UCLA-0403021-01</secondary_id>
    <secondary_id>MILLENNIUM-VEL-04-108</secondary_id>
    <secondary_id>MILLENNIUM-EBV-NHL-01</secondary_id>
    <nct_id>NCT00093704</nct_id>
  </id_info>
  <brief_title>Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma</brief_title>
  <official_title>EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary&#xD;
      for their growth. The Epstein Barr virus can cause cancer and lymphoproliferative disorders.&#xD;
      Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Giving ganciclovir&#xD;
      together with bortezomib may kill more Epstein Barr virus-infected cancer cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving bortezomib together with ganciclovir&#xD;
      works in treating patients with relapsed or refractory Epstein Barr virus-positive lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Maximum Tolerated Dose (MTD) of bortezomib in patients with relapsed or refractory&#xD;
           Epstein Barr virus-positive lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the antitumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, open-label, dose-escalation study of bortezomib.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive&#xD;
      ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3&#xD;
      courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-9 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study could not recruit any more patients&#xD;
  </why_stopped>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of Bortezomib in patients with relapsed or refractory EBV + lymphomas</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bortezomib in inducing lytic gene expression in EBV-infected lymphoma cells</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <arm_group>
    <arm_group_label>Bortezomib + ganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib + ganciclovir</intervention_name>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.</description>
    <arm_group_label>Bortezomib + ganciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed Epstein Barr virus-positive lymphoma, including the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Post-transplantation lymphoma&#xD;
&#xD;
               -  Burkitt's lymphoma&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
               -  T-/NK-cell lymphoma&#xD;
&#xD;
          -  Unresponsive to, or relapsed after, at least 1 prior chemotherapy regimen&#xD;
&#xD;
          -  Bidimensionally measurable disease by CT scan&#xD;
&#xD;
          -  At least 1 lesion ≥ 1.5 cm in the greatest diameter&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
          -  Life expectancy More than 3 months&#xD;
&#xD;
          -  Hematopoietic&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm^3 (no growth factor support within the past&#xD;
                  4 weeks)&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 50,000/mm^3 (no platelet transfusions within the past 4 weeks)&#xD;
&#xD;
          -  Hepatic&#xD;
&#xD;
               -  Bilirubin ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times ULN (5 times ULN in patients with liver involvement)&#xD;
&#xD;
               -  No active hepatitis B or C&#xD;
&#xD;
          -  Renal&#xD;
&#xD;
               -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Sodium &gt; 130 mmol/L&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery unless fully recovered&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary or secondary CNS lymphoma or HIV-related lymphoma&#xD;
&#xD;
          -  known brain metastases&#xD;
&#xD;
          -  myocardial infarction within the past 6 months&#xD;
&#xD;
          -  acute ischemia or new conduction system abnormalities by electrocardiogram&#xD;
&#xD;
          -  symptomatic congestive heart failure&#xD;
&#xD;
          -  unstable angina pectoris&#xD;
&#xD;
          -  cardiac arrhythmia&#xD;
&#xD;
          -  hospitalized&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  other uncontrolled illness&#xD;
&#xD;
          -  ongoing or active systemic infection&#xD;
&#xD;
          -  psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  history of allergic reaction attributable to compounds of similar chemical or&#xD;
             biological composition to study drugs&#xD;
&#xD;
          -  sensitivity to boron, mannitol, bortezomib, or ganciclovir&#xD;
&#xD;
          -  concurrent corticosteroids (≥ 10 mg of prednisone or equivalent)&#xD;
&#xD;
          -  concurrent radiotherapy&#xD;
&#xD;
          -  other concurrent anticancer therapy&#xD;
&#xD;
          -  other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven De Vos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

